Iron Chelator
-
Surveys
TIF STUDY | Desferioxamine Usage Survey
Desferioxamine is crucial in managing iron overload for many patients with thalassaemia and related blood conditions. Recently, the Thalassaemia International Federation (TIF) has received growing reports of shortages in Desferioxamine,…
Read More » -
News
FDA Approves New Formulation for Ferriprox (Deferiprone) Twice-a-Day Tablets
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment…
Read More »